<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00370253</url>
  </required_header>
  <id_info>
    <org_study_id>NA-TER</org_study_id>
    <nct_id>NCT00370253</nct_id>
  </id_info>
  <brief_title>Noradrenalin vs Terlipressin in Hepatorenal Syndrome</brief_title>
  <official_title>Noradrenalin vs Terlipressin in Patients With Hepatorenal Syndrome.A Prospective, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Turin, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether noradrenalin is as effective and safe as&#xD;
      terlipressin in the treatment of hepatorenal syndrome&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatorenal syndrome (HRS) is a major complication of cirrhosis; it is characterized by&#xD;
      functional renal failure and poor prognosis. Arterial dilation is a key pathogenic event of&#xD;
      HRS, leading to reduction of the effective blood volume, homeostatic activation of vasoactive&#xD;
      systems and renal vasoconstriction with decrease in renal blood flow. The clinical signs of&#xD;
      HRS vary depending on the clinical pattern. HRS type 1 is characterized by a rapidly&#xD;
      progressive renal failure; HRS type 2 by a moderate and more stable renal failure. HRS type 1&#xD;
      has a very poor short term prognosis, with a median survival of only about 2 weeks; patients&#xD;
      with HRS type 2 have a median survival of about 6 months. The management of HRS still&#xD;
      constitutes a major challenge. Liver transplantation is the ideal treatment, but it has&#xD;
      important inherent drawbacks, such as the organ shortage and the time needed to perform the&#xD;
      transplant, that is too long to consent the survival of these patients. The management of HRS&#xD;
      has focused on improving renal function, thus extending patients survival and allowing the&#xD;
      performance of the liver transplant. In the last years, remarkable results have been obtained&#xD;
      using vasoconstrictor drugs. By improving the effective blood volume, vasoconstrictors induce&#xD;
      the suppression of homeostatic vasoactive systems and increase renal blood flow and&#xD;
      glomerular filtration rate.Among vasoconstrictors, terlipressin, a V1 vasopressin agonist,&#xD;
      has currently the best efficacy pedigree. However, it is expensive and is not available in&#xD;
      many countries, including North America. More recently, it was suggested that&#xD;
      alpha-adrenergic drugs such noradrenalin and midodrine may be also effective in HRS.&#xD;
      Noradrenalin would have the potential advantage of wider availability and of lower cost. The&#xD;
      current prospective randomized study was undertaken to assess the efficacy and safety of&#xD;
      noradrenalin vs terlipressin in patients with HRS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal function at the beginning and at the end of therapy</measure>
    <time_frame>two weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Circulatory function</measure>
    <time_frame>two weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hepatorenal Syndrome</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Terlipressin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Noradrenalin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>1mg/4 h per day</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Noradrenalin</intervention_name>
    <description>0,1 mcg/kg/min</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hepatorenal syndrome&#xD;
&#xD;
          -  Age: 18-75 years&#xD;
&#xD;
          -  Informed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multinodular hepatocellular carcinoma (more than 3 nodules)&#xD;
&#xD;
          -  Portal vein thrombosis&#xD;
&#xD;
          -  Ongoing bacterial infection&#xD;
&#xD;
          -  Ongoing or recent (less than one week) bleeding&#xD;
&#xD;
          -  Cardio-pulmonary failure&#xD;
&#xD;
          -  Coronary artery disease&#xD;
&#xD;
          -  Peripheral artery disease&#xD;
&#xD;
          -  Arterial hypertension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Rizzetto, MD</last_name>
    <role>Study Director</role>
    <affiliation>Division of Gastroenterology and Hepatology, San Giovanni Battista Hospital, Turin, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Giovanni Battista Hospital</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002 Oct;36(4 Pt 1):941-8.</citation>
    <PMID>12297842</PMID>
  </reference>
  <reference>
    <citation>Duvoux C, Zanditenas D, Hézode C, Chauvat A, Monin JL, Roudot-Thoraval F, Mallat A, Dhumeaux D. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology. 2002 Aug;36(2):374-80.</citation>
    <PMID>12143045</PMID>
  </reference>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>August 30, 2006</study_first_submitted>
  <study_first_submitted_qc>August 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2006</study_first_posted>
  <last_update_submitted>April 9, 2008</last_update_submitted>
  <last_update_submitted_qc>April 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Mario Rizzetto</name_title>
    <organization>University of Turin</organization>
  </responsible_party>
  <keyword>hepatorenal syndrome</keyword>
  <keyword>ascites</keyword>
  <keyword>portal hypertension</keyword>
  <keyword>cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatorenal Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

